Oncology

Latest News

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

December 10th 2024

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg
Prior Authorization Delays Cause Serious Harm to Patients With Cancer

December 4th 2024

Highlights From ACCC Annual Meeting & Cancer Center Business Summit
ICYMI: Highlights From ACCC Spring 2024

December 4th 2024

FDA approval. | Image Credit: syahrir - stock.adobe.com
FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

November 21st 2024

Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com
Drivers of Aggression Identified in Double-Expressor DLBCL

November 19th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer
September 13th 2024

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer

Alana Hippensteele
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
Dax Kurbegov, MD, senior vice president, Sarah Cannon Cancer Network
September 12th 2024

Dr Dax Kurbegov on Gaps Between Payers, Health Systems, and Providers in Oncology

Rose McNulty
Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.
Brain MRI | Image credit: stockdevil - stock.adobe.com
September 11th 2024

TIM3 Targeted Immunotherapy Shows Promise in Pediatric Brain Cancer

Pearl Steinzor
Breakthrough research identifies TIM3 as a key target in MAPK-activated pediatric gliomas, offering new hope for more effective immunotherapy treatments.
AJMC
September 6th 2024

The Feasibility and Equity of Text Messaging to Determine Patient Eligibility for Lung Cancer Screening

Ilona Fridman, PhD Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C Christine M. Neslund-Dudas, PhD Jennifer Elston Lafata, PhD
Text messaging shows promise for assessing smoking status and identifying lung cancer screening eligibility, particularly among middle-aged, educated individuals with medium or high income. However, a multimodal approach is crucial for equitable implementation of such a program.
Doctor and patient with breast cancer. | Image Credit: Pixel-Shot - stock.adobe.com .jpeg
September 3rd 2024

The Connection Between Cancer Treatment Choices and Suicide Mortality

Pearl Steinzor
Patients with cancer who forego surgery have higher suicide incidence than those who undergo treatment, a study finds.
When to Pause Before Recommending Cannabis to Patients With Cancer
September 1st 2024

When to Pause Before Recommending Cannabis to Patients With Cancer

Laura Joszt, MA
Despite lacking some data, there is some information on which patients with cancer shouldn’t be recommended cannabis or certain cannabis products, said Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Matthew Nielsen, MD
August 31st 2024

Using Active Surveillance to Spare Men From Unneeded Prostate Cancer Treatment

Laura Joszt, MA
Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.
Neal D. Shore, MD
August 28th 2024

Evaluating Which Patients With Prostate Cancer Will Benefit From Triplet Therapy

Laura Joszt, MA
Not all patients will want to take triplet therapy, but those with high-volume prostate cancer who are chemotherapy eligible are usually a good fit, explained Neal D. Shore, MD, FACS.
Value-based care concept | Image credit: momius - stock.adobe.com
August 27th 2024

Thyme Care Strengthens Value-Based Oncology Care With Dr Lalan Wilfong

Pearl Steinzor
Thyme Care welcomes its new senior vice president to lead initiatives in value-based oncology care.
Health care concept on $100 dollar bill | Image credit: ricardoreitmeyer - stock.adobe.com
August 26th 2024

The Role of Community, Structural Factors in Financial Hardship Among Cancer Survivors

Pearl Steinzor
Social vulnerability and economic disadvantages exacerbate financial hardship in cancer survivors, according to one study.
Marie Parish, PharmD, BCOP, screenshot
August 22nd 2024

Using Cannabis as a Bridge for Symptom Management in Cancer

Laura Joszt, MA
Patients with cancer will never completely replace existing pain regimens, but cannabis could be used in conjunction, explained Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Psychologist holding arm of patient in support | Image credit: pressmaster - stock.adobe.com
August 21st 2024

Spouses of Patients With Cancer Face Elevated Suicide Risk, Study Finds

Pearl Steinzor
Spouses of patients with cancer face a significantly higher risk of suicide attempts and suicide death, especially within the first year of diagnosis, according to one study.
FDA approval | Image Credit: cartoon-stock.adobe.com
August 16th 2024

FDA Approves Durvalumab Combination Therapy for Resectable Early-Stage NSCLC

Pearl Steinzor
The newly approved treatment regimen demonstrated a significant reduction in recurrence risk in patients with resectable non–small cell lung cancer (NSCLC).
Andrew Hantel, MD
August 14th 2024

We Need to Lower Barriers to and Burdens of Trial Entry: Dr Andrew Hantel

Kyle Munz
Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.
AJMC
August 13th 2024

The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting

Julie Patterson, PharmD, PhD John Michael O’Brien, PharmD, MPH Jonathan D. Campbell, PhD
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.
FDA Approved
August 8th 2024

FDA Approves Denileukin Difitox for Refractory Cutaneous T-Cell Lymphoma

Julia Bonavitacola
Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy.
Brain tumor 3D illustration | Imaged credit: Dr_Microbe - stock.adobe.com
August 7th 2024

Vorasidenib Approved by FDA for Grade 2 IDH-Mutant Glioma

Pearl Steinzor
Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval.
Medical mammogram exam | Image Credit: TeraVector - stock.adobe.com
August 6th 2024

COVID-19 Disrupted Breast Cancer Screenings, Exacerbated Disparities

Cameron Santoro
The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
August 6th 2024

Patients With Endometriosis May Have Higher Ovarian Cancer Risk

Brooke McCormick
Patients with endometriosis have a 4.2-fold greater ovarian cancer risk, highlighting the need for further research into the biological links between endometriosis subtypes and ovarian cancer.
Lung cancer diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
August 1st 2024

NSCLC Study Highlights Need for Adjuvant Trials in Early-Stage Disease

Maggie L. Shaw
Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.
Amit Singal, MD, UT Southwestern Medical Center
August 1st 2024

Addressing Ongoing Disparities in Liver Cancer Care: Dr Amit Singal

Rose McNulty
Amit Singal, MD, medical director of the Liver Tumor Program and chief of hepatology at UT Southwestern Medical Center, discusses his research on disparities in hepatocellular carcinoma care in the US.
Pink ribbon for breast cancer. | Image Credit: Andrey Popov - stock.adobe.com
July 31st 2024

Black Women With Obesity, Elevated Leptin Levels at Higher Risk for Breast Cancer

Cameron Santoro
The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.
cancer patient enjoying life | Image credit: VadimGuzhva - stock.adobe.com
July 29th 2024

Protein Signatures Could Improve Patient Outcome Predictions in Soft Tissue Sarcomas

Skylar Jeremias
A study demonstrates the value of incorporating protein signatures in creating more advanced prediction tools for patient outcomes.
FDA | Image Credit: wladimir1804-stock.adobe.com
July 28th 2024

ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC

Caroline Seymour
Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 28th 2024

Addressing Drug Shortages: Enhancing Buffer Stock, Transparency to Mitigate Future Crises

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses possible federal policies to help mitigate ongoing and future cancer drug shortages.
Female patient holding up breast cancer awareness ribbon | Image Credit: Pixel-Shot - stock.adobe.com
July 27th 2024

Study: Breast Cancer Immunotherapy Trials Make Modest Clinical Impact

Brooke McCormick
Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.
AI models can be useful tools for clinicians, helping assess risk in patients with HCC to inform disease management. | Image credit: ipopba - stock.adobe.com
July 26th 2024

AI Model Precisely Identifies HCC Recurrence Risk Factors

Rose McNulty
Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
July 25th 2024

Effective Solutions for Drug Shortages: Market Incentives, Infrastructure, and Quality Management

Pearl Steinzor
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, discusses different policy approaches to address the ongoing cancer drug shortage.
Mammogram screening | Image Credit: okrasiuk - stock.adobe.com
July 25th 2024

Risks, Benefits of Bilateral Mastectomy for Unilateral Breast Cancer

Cameron Santoro
Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.
Colon | Image credit: New Africa - stock.adobe.com
July 24th 2024

Metabolic Dysfunction–Associated Steatotic Liver Disease Linked With CRC

Julia Bonavitacola
Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.
<12345678
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo